Abstract | BACKGROUND:
Chronic subdural hematoma (cSDH) is a common neurosurgical disease. It is often considered to be a rather benign entity. In spite of well established surgical procedures cSDH is complicated by a recurrence rate up to 30%. Since glucocorticoids have been used for treatment of cSDH in 1962 their role is still discussed controversially in lack of evident data. On the basis of the ascertained inflammation cycle in cSDH dexamethasone will be an ideal substance for a short lasting, concomitant treatment protocol. OBJECTIVE: to test the efficacy of dexamethasone on reduction inthe reoperation rate of cSDH. METHODS/DESIGN: The study is designed as a double-blind randomized placebo-controlled trial 820 patients who are operated for cSDH and from the age of 25 years are included after obtaining informed consent. They are randomized for administration of dexamethasone (16-16-12-12-8-4 mg/d) or placebo ( maltodextrin) during the first 48 hours after surgery. The type I error is 5% and the type II error is 20%. The primary endpoint is the reoperation within 12 weeks postoperative. DISCUSSION: TRIAL REGISTRATION: EudraCT 201100354442.
|
Authors | Stephan Emich, Bernd Richling, Marc R McCoy, Rahman Abdul Al-Schameri, Feng Ling, Liyong Sun, Yabing Wang, Wolfgang Hitzl |
Journal | Trials
(Trials)
Vol. 15
Pg. 6
(Jan 06 2014)
ISSN: 1745-6215 [Electronic] England |
PMID | 24393328
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Glucocorticoids
- Dexamethasone
|
Topics |
- Adult
- Austria
- China
- Clinical Protocols
- Dexamethasone
(administration & dosage, adverse effects)
- Double-Blind Method
- Drug Administration Schedule
- Glucocorticoids
(administration & dosage, adverse effects)
- Hematoma, Subdural, Chronic
(diagnosis, drug therapy, surgery)
- Humans
- Reoperation
- Research Design
- Secondary Prevention
- Time Factors
- Treatment Outcome
|